# PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2

> **NCT05011396** · PHASE3 · TERMINATED · sponsor: **VistaGen Therapeutics, Inc.** · enrollment: 228 (actual)

## Conditions studied

- Social Anxiety Disorder

## Interventions

- **DRUG:** PH94B Nasal Spray
- **DRUG:** Placebo Nasal Spray

## Key facts

- **NCT ID:** NCT05011396
- **Lead sponsor:** VistaGen Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-30
- **Primary completion:** 2022-08-16
- **Final completion:** 2022-08-16
- **Target enrollment:** 228 (ACTUAL)
- **Why stopped:** Study stopped by the sponsor for business reasons and not due to any safety concerns with PH94B
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05011396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05011396, "PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05011396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*